{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:41:17Z","timestamp":1780731677898,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203145"],"award-info":[{"award-number":["82203145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203145"],"award-info":[{"award-number":["82203145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203145"],"award-info":[{"award-number":["82203145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203145"],"award-info":[{"award-number":["82203145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Yunnan Revitalization Talent Support Program","award":["XDYC-QNRC-2023-0440"],"award-info":[{"award-number":["XDYC-QNRC-2023-0440"]}]},{"name":"Yunnan Revitalization Talent Support Program","award":["XDYC-QNRC-2023-0440"],"award-info":[{"award-number":["XDYC-QNRC-2023-0440"]}]},{"name":"Yunnan Revitalization Talent Support Program","award":["XDYC-QNRC-2023-0440"],"award-info":[{"award-number":["XDYC-QNRC-2023-0440"]}]},{"name":"Joint Special Funds for the Department of Science and Technology of Yunnan Province\u2011Kunming Medical University","award":["202401AY070001-012"],"award-info":[{"award-number":["202401AY070001-012"]}]},{"name":"Joint Special Funds for the Department of Science and Technology of Yunnan Province\u2011Kunming Medical University","award":["202401AY070001-012"],"award-info":[{"award-number":["202401AY070001-012"]}]},{"name":"Joint Special Funds for the Department of Science and Technology of Yunnan Province\u2011Kunming Medical University","award":["202401AY070001-012"],"award-info":[{"award-number":["202401AY070001-012"]}]},{"name":"Basic Research Project of Yunnan Province","award":["202301AT070041"],"award-info":[{"award-number":["202301AT070041"]}]},{"name":"Basic Research Project of Yunnan Province","award":["202301AT070259"],"award-info":[{"award-number":["202301AT070259"]}]},{"name":"Basic Research Project of Yunnan Province","award":["202301AT070041"],"award-info":[{"award-number":["202301AT070041"]}]},{"name":"Basic Research Project of Yunnan Province","award":["202301AT070041"],"award-info":[{"award-number":["202301AT070041"]}]},{"name":"Yunnan Provincial Clinical Medical Research Center for Gynecological and Obstetrical Diseases","award":["2023YJZX-FC08"],"award-info":[{"award-number":["2023YJZX-FC08"]}]},{"name":"Yunnan Provincial Clinical Medical Research Center for Gynecological and Obstetrical Diseases","award":["2023YJZX-FC08"],"award-info":[{"award-number":["2023YJZX-FC08"]}]},{"name":"Yunnan Provincial Clinical Medical Research Center for Gynecological and Obstetrical Diseases","award":["2023YJZX-FC08"],"award-info":[{"award-number":["2023YJZX-FC08"]}]},{"name":"National Key Clinical Specialty of Gynecology\u30fbFirst People\u2019s Hospital of Yunnan Province","award":["2022FKZDZK-16"],"award-info":[{"award-number":["2022FKZDZK-16"]}]},{"name":"National Key Clinical Specialty of Gynecology\u30fbFirst People\u2019s Hospital of Yunnan Province","award":["2022FKZDZK-16"],"award-info":[{"award-number":["2022FKZDZK-16"]}]},{"name":"National Key Clinical Specialty of Gynecology\u30fbFirst People\u2019s Hospital of Yunnan Province","award":["2022FKZDZK-16"],"award-info":[{"award-number":["2022FKZDZK-16"]}]},{"name":"Yunnan Provincial Clinical Medical Center for Reproductive, Gynecological and Obstetrical Diseases","award":["2022LCZXKF-SZ08"],"award-info":[{"award-number":["2022LCZXKF-SZ08"]}]},{"name":"Yunnan Provincial Clinical Medical Center for Reproductive, Gynecological and Obstetrical Diseases","award":["2022LCZXKF-SZ08"],"award-info":[{"award-number":["2022LCZXKF-SZ08"]}]},{"name":"Yunnan Provincial Clinical Medical Center for Reproductive, Gynecological and Obstetrical Diseases","award":["2022LCZXKF-SZ08"],"award-info":[{"award-number":["2022LCZXKF-SZ08"]}]},{"name":"High-level Personnel Introduction Fund of the First People\u2019s Hospital of Yunnan Province","award":["2022-KHRCBZ-B05"],"award-info":[{"award-number":["2022-KHRCBZ-B05"]}]},{"name":"High-level Personnel Introduction Fund of the First People\u2019s Hospital of Yunnan Province","award":["2022-KHRCBZ-B05"],"award-info":[{"award-number":["2022-KHRCBZ-B05"]}]},{"name":"High-level Personnel Introduction Fund of the First People\u2019s Hospital of Yunnan Province","award":["2022-KHRCBZ-B05"],"award-info":[{"award-number":["2022-KHRCBZ-B05"]}]},{"name":"Doctoral Research Fund Program of the First People\u2019s Hospital of Yunnan Province","award":["KHBS-2022-026"],"award-info":[{"award-number":["KHBS-2022-026"]}]},{"name":"Doctoral Research Fund Program of the First People\u2019s Hospital of Yunnan Province","award":["KHBS-2022-026"],"award-info":[{"award-number":["KHBS-2022-026"]}]},{"name":"Doctoral Research Fund Program of the First People\u2019s Hospital of Yunnan Province","award":["KHBS-2022-026"],"award-info":[{"award-number":["KHBS-2022-026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02794-2","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T14:13:03Z","timestamp":1749305583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CEBPB regulates ERK1\/2 activity through SOS1 and contributes to ovarian cancer progression"],"prefix":"10.1007","volume":"42","author":[{"given":"Jiahong","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqing","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"2794_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1265","author":"S Li","year":"2021","unstructured":"Li S, Hongfu Z. 823TiP Fluzoparide combined with apatinib mesylate in the treatment of platinum resistant recurrent ovarian cancer: a single arm, single center, prospective clinical study. Ann Oncol. 2021. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1265.","journal-title":"Ann Oncol"},{"key":"2794_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s13402-020-00513-9","volume":"43","author":"M Yousefi","year":"2020","unstructured":"Yousefi M, Dehghani S, Nosrati R, Ghanei M, Salmaninejad A, Rajaie S, Hasanzadeh M, Pasdar A. Current insights into the metastasis of epithelial ovarian cancer \u2014 hopes and hurdles. Cell Oncol (Dordr). 2020;43:515\u201338. https:\/\/doi.org\/10.1007\/s13402-020-00513-9.","journal-title":"Cell Oncol (Dordr)"},{"key":"2794_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN. Cancer statistics. CA A Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA A Cancer J Clin"},{"key":"2794_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286\u2013287","author":"D Sonkin","year":"2024","unstructured":"Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286\u2013287:18\u201324. https:\/\/doi.org\/10.1016\/j.cancergen.2024.06.002.","journal-title":"Cancer Genet"},{"key":"2794_CR5","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1002\/cncr.33829","volume":"127","author":"SP Huepenbecker","year":"2021","unstructured":"Huepenbecker SP, Sun CC, Fu S, Zhao H. Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States. Cancer. 2021;127:4151\u201360. https:\/\/doi.org\/10.1002\/cncr.33829.","journal-title":"Cancer"},{"key":"2794_CR6","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1148\/rg.2021210005","volume":"41","author":"S Rao","year":"2021","unstructured":"Rao S, Smith DA. Past, present, and future of serum tumor markers in management of ovarian cancer: a guide for the radiologist. Radiographics. 2021;41:1839\u201356. https:\/\/doi.org\/10.1148\/rg.2021210005.","journal-title":"Radiographics"},{"key":"2794_CR7","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/s1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384. https:\/\/doi.org\/10.1016\/s1470-2045(17)30469-2.","journal-title":"Lancet Oncol"},{"key":"2794_CR8","doi-asserted-by":"publisher","DOI":"10.1017\/s1462399409001033","volume":"11","author":"CA Zahnow","year":"2009","unstructured":"Zahnow CA. CCAAT\/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med. 2009;11: e12. https:\/\/doi.org\/10.1017\/s1462399409001033.","journal-title":"Expert Rev Mol Med"},{"key":"2794_CR9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1089\/gtmb.2018.0291","volume":"23","author":"H Li","year":"2019","unstructured":"Li H, Yang F, Chai L, Zhang L, Li S, Xu Z, Kong L. CCAAT\/enhancer binding protein \u03b2-mediated mmp3 upregulation promotes esophageal squamous cell cancer invasion in vitro and is associated with metastasis in human patients. Genet Test Mol Biomarkers. 2019;23:304\u20139. https:\/\/doi.org\/10.1089\/gtmb.2018.0291.","journal-title":"Genet Test Mol Biomarkers"},{"key":"2794_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells8020145","author":"L Ji Hae","year":"2019","unstructured":"Ji Hae L, Jee Young S, Eun Kyung C, Hye-Jung Y, Bo K, Eun Kyung H, Byung-Kiu P, Yong-Nyun K, Seung Bae R, Kyungsil Y. C\/EBP\u03b2 is a transcriptional regulator of Wee1 at the G2\/M phase of the cell cycle. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8020145.","journal-title":"Cells"},{"key":"2794_CR11","doi-asserted-by":"publisher","first-page":"1111522","DOI":"10.3389\/fonc.2023.1111522","volume":"13","author":"MG Matherne","year":"2023","unstructured":"Matherne MG, Phillips ES, Embrey SJ, Burke CM, Machado HL. Emerging functions of C\/EBP\u03b2 in breast cancer. Front Oncol. 2023;13:1111522. https:\/\/doi.org\/10.3389\/fonc.2023.1111522.","journal-title":"Front Oncol"},{"key":"2794_CR12","doi-asserted-by":"publisher","first-page":"5802082","DOI":"10.1155\/2021\/5802082","volume":"2021","author":"S Yang","year":"2021","unstructured":"Yang S, Wang J, Cheng R, Pang B, Sun P. LINC00035 transcriptional regulation of SLC16A3 via CEBPB affects glycolysis and cell apoptosis in ovarian cancer. Evid-Based Complement Altern Med. 2021;2021:5802082. https:\/\/doi.org\/10.1155\/2021\/5802082.","journal-title":"Evid-Based Complement Altern Med"},{"key":"2794_CR13","doi-asserted-by":"publisher","first-page":"23748","DOI":"10.18632\/oncotarget.4250","volume":"6","author":"YH Wu","year":"2015","unstructured":"Wu YH, Chang TH, Huang YF, Chen CC, Chou CY. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt\/c\/EBP\u03b2 pathway and PDK1 stabilization. Oncotarget. 2015;6:23748\u201363. https:\/\/doi.org\/10.18632\/oncotarget.4250.","journal-title":"Oncotarget"},{"key":"2794_CR14","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152\u20138. https:\/\/doi.org\/10.1126\/science.aam7344.","journal-title":"Science"},{"key":"2794_CR15","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1038\/s41388-021-01788-4","volume":"40","author":"J Tan","year":"2021","unstructured":"Tan J, Zheng X, Li M. C\/EBP\u03b2 promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer. Oncogene. 2021;40:3845\u201358. https:\/\/doi.org\/10.1038\/s41388-021-01788-4.","journal-title":"Oncogene"},{"key":"2794_CR16","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41467-018-03590-5","volume":"9","author":"D Liu","year":"2018","unstructured":"Liu D, Zhang XX, Li MC, Cao CH, Wan DY, Xi BX, Tan JH, Wang J, Yang ZY, Feng XX, Ye F, Chen G, Wu P, Xi L, Wang H, Zhou JF, Feng ZH, Ma D, Gao QL. C\/EBP\u03b2 enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat Commun. 2018;9:1739. https:\/\/doi.org\/10.1038\/s41467-018-03590-5.","journal-title":"Nat Commun"},{"key":"2794_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0968-0004(93)90031-h","volume":"18","author":"J Schlessinger","year":"1993","unstructured":"Schlessinger J. How receptor tyrosine kinases activate Ras. Trends Biochem Sci. 1993;18:273\u20135. https:\/\/doi.org\/10.1016\/0968-0004(93)90031-h.","journal-title":"Trends Biochem Sci"},{"key":"2794_CR18","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1091\/mbc.e05-12-1104","volume":"17","author":"N Zarich","year":"2006","unstructured":"Zarich N, Oliva JL, Mart\u00ednez N, Jorge R, Ballester A, Guti\u00e9rrez-Eisman S, Garc\u00eda-Vargas S, Rojas JM. Grb2 is a negative modulator of the intrinsic Ras-GEF activity of hSos1. Mol Biol Cell. 2006;17:3591\u20137. https:\/\/doi.org\/10.1091\/mbc.e05-12-1104.","journal-title":"Mol Biol Cell"},{"key":"2794_CR19","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ncomms2173","volume":"3","author":"HH Jeng","year":"2012","unstructured":"Jeng HH, Taylor LJ, Bar-Sagi D. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat Commun. 2012;3:1168. https:\/\/doi.org\/10.1038\/ncomms2173.","journal-title":"Nat Commun"},{"key":"2794_CR20","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1073\/pnas.90.6.2207","volume":"90","author":"T Nakajima","year":"1993","unstructured":"Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T, Akira S. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci USA. 1993;90:2207\u201311. https:\/\/doi.org\/10.1073\/pnas.90.6.2207.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2794_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1073\/pnas.012437299","volume":"99","author":"S Zhu","year":"2002","unstructured":"Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC. CCAAT\/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci USA. 2002;99:207\u201312. https:\/\/doi.org\/10.1073\/pnas.012437299.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2794_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1126\/science.256.5055.370","volume":"256","author":"M Wegner","year":"1992","unstructured":"Wegner M, Cao Z, Rosenfeld MG. Calcium-regulated phosphorylation within the leucine zipper of C\/EBP beta. Science. 1992;256:370\u20133. https:\/\/doi.org\/10.1126\/science.256.5055.370.","journal-title":"Science"},{"key":"2794_CR23","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1194\/jlr.M500337-JLR200","volume":"46","author":"NV Giltiay","year":"2005","unstructured":"Giltiay NV, Karakashian AA, Alimov AP, Ligthle S, Nikolova-Karakashian MN. Ceramide- and ERK-dependent pathway for the activation of CCAAT\/enhancer binding protein by interleukin-1beta in hepatocytes. J Lipid Res. 2005;46:2497\u2013505. https:\/\/doi.org\/10.1194\/jlr.M500337-JLR200.","journal-title":"J Lipid Res"},{"key":"2794_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2023.105626","author":"C Peng","year":"2023","unstructured":"Peng C, Zhong F, Ling O, Yuanjing Z, Shuyi S, Hengrui L, Weichun Z, Gin Gin G, Guimin Z, Meicun Y. Syzygium aromaticum enhances innate immunity by triggering macrophage M1 polarization and alleviates Helicobacter pylori-induced inflammation. J Funct Foods. 2023. https:\/\/doi.org\/10.1016\/j.jff.2023.105626.","journal-title":"J Funct Foods"},{"key":"2794_CR25","doi-asserted-by":"publisher","first-page":"1416794","DOI":"10.3389\/fmicb.2024.1416794","volume":"15","author":"L Ou","year":"2024","unstructured":"Ou L, Hao Y, Liu H, Zhu Z, Li Q, Chen Q, Wei R, Feng Z, Zhang G, Yao M. Chebulinic acid isolated from aqueous extracts of Terminalia chebula Retz inhibits Helicobacter pylori infection by potential binding to Cag A protein and regulating adhesion. Front Microbiol. 2024;15:1416794. https:\/\/doi.org\/10.3389\/fmicb.2024.1416794.","journal-title":"Front Microbiol"},{"key":"2794_CR26","doi-asserted-by":"publisher","first-page":"107558","DOI":"10.1016\/j.pharmthera.2020.107558","volume":"212","author":"H Liu","year":"2020","unstructured":"Liu H, Dilger JP, Lin J. Effects of local anesthetics on cancer cells. Pharmacol Ther. 2020;212:107558. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107558.","journal-title":"Pharmacol Ther"},{"key":"2794_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2147\/pgpm.s397827","volume":"16","author":"L Zhong","year":"2023","unstructured":"Zhong L, Yin R, Song L. Resistance to PARP inhibitors after first-line platinum-based chemotherapy in a patient with advanced ovarian cancer with a pathogenic somatic BRCA1 mutation. Pharmacogenom Personal Med. 2023;16:195\u2013200. https:\/\/doi.org\/10.2147\/pgpm.s397827.","journal-title":"Pharmacogenom Personal Med"},{"key":"2794_CR28","doi-asserted-by":"publisher","first-page":"175883591984975","DOI":"10.1177\/1758835919849753","volume":"11","author":"JA Ledermann","year":"2019","unstructured":"Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ther Adv Med Oncol. 2019;11:1758835919849753. https:\/\/doi.org\/10.1177\/1758835919849753.","journal-title":"Ther Adv Med Oncol"},{"key":"2794_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5301\/tj.5000558","volume":"102","author":"J McLachlan","year":"2016","unstructured":"McLachlan J, George A, Banerjee S. The current status of PARP inhibitors in ovarian cancer. Tumori. 2016;102:433\u201340. https:\/\/doi.org\/10.5301\/tj.5000558.","journal-title":"Tumori"},{"key":"2794_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40259-019-00347-4","volume":"33","author":"SA Cook","year":"2019","unstructured":"Cook SA, Tinker AV. PARP inhibitors and the evolving landscape of ovarian cancer management: a review. BioDrugs: Clin Immunother Biopharm Gene Ther. 2019;33:255\u201373. https:\/\/doi.org\/10.1007\/s40259-019-00347-4.","journal-title":"BioDrugs: Clin Immunother Biopharm Gene Ther"},{"key":"2794_CR31","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.cd-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D\u2019Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5:1137\u201354. https:\/\/doi.org\/10.1158\/2159-8290.cd-15-0714.","journal-title":"Cancer Discov"},{"key":"2794_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","volume":"19","author":"H Zhu","year":"2020","unstructured":"Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020;19:49. https:\/\/doi.org\/10.1186\/s12943-020-01167-9.","journal-title":"Mol Cancer"},{"key":"2794_CR33","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1038\/s41388-018-0190-7","volume":"37","author":"SK Basu","year":"2018","unstructured":"Basu SK, Gonit M, Salotti J, Chen J, Bhat A, Gorospe M, Viollet B. A RAS-CaMKK\u03b2-AMPK\u03b12 pathway promotes senescence by licensing post-translational activation of C\/EBP\u03b2 through a novel 3\u2019UTR mechanism. Oncogene. 2018;37:3528\u201348. https:\/\/doi.org\/10.1038\/s41388-018-0190-7.","journal-title":"Oncogene"},{"key":"2794_CR34","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1073\/pnas.1812963116","volume":"116","author":"RC Hillig","year":"2019","unstructured":"Hillig RC, Sautier B, Schroeder J, Moosmayer D, Hilpmann A, Stegmann CM, Werbeck ND, Briem H, Boemer U, Weiske J, Badock V, Mastouri J, Petersen K, Siemeister G, Kahmann JD, Wegener D, B\u00f6hnke N, Eis K, Graham K, Wortmann L, von Nussbaum F, Bader B. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci USA. 2019;116:2551\u201360. https:\/\/doi.org\/10.1073\/pnas.1812963116.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2794_CR35","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1021\/jm501660t","volume":"58","author":"JJ Winter","year":"2015","unstructured":"Winter JJ, Anderson M, Blades K, Brassington C, Breeze AL, Chresta C, Embrey K, Fairley G, Faulder P, Finlay MR, Kettle JG, Nowak T, Overman R, Patel SJ, Perkins P, Spadola L, Tart J, Tucker JA, Wrigley G. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation. J Med Chem. 2015;58:2265\u201374. https:\/\/doi.org\/10.1021\/jm501660t.","journal-title":"J Med Chem"},{"key":"2794_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1158\/1535-7163.mct-17-0666","volume":"17","author":"JE Howes","year":"2018","unstructured":"Howes JE, Akan DT, Burns MC, Rossanese OW, Waterson AG, Fesik SW. Small molecule-mediated activation of RAS elicits biphasic modulation of Phospho-ERK levels that are regulated through negative feedback on SOS1. Mol Cancer Ther. 2018;17:1051\u201360. https:\/\/doi.org\/10.1158\/1535-7163.mct-17-0666.","journal-title":"Mol Cancer Ther"},{"key":"2794_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/bs.acr.2021.07.008","volume":"153","author":"JN Diehl","year":"2022","unstructured":"Diehl JN, Hibshman PS, Ozkan-Dagliyan I, Goodwin CM, Howard SV, Cox AD, Der CJ. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. Adv Cancer Res. 2022;153:101\u201330. https:\/\/doi.org\/10.1016\/bs.acr.2021.07.008.","journal-title":"Adv Cancer Res"},{"key":"2794_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1947601911407328","volume":"2","author":"I Wortzel","year":"2011","unstructured":"Wortzel I, Seger R. The ERK cascade: distinct functions within various subcellular organelles. Genes Cancer. 2011;2:195\u2013209. https:\/\/doi.org\/10.1177\/1947601911407328.","journal-title":"Genes Cancer"},{"key":"2794_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","volume":"12","author":"W Zhang","year":"2002","unstructured":"Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12:9\u201318. https:\/\/doi.org\/10.1038\/sj.cr.7290105.","journal-title":"Cell Res"},{"key":"2794_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12263-022-00705-y","volume":"17","author":"M Peng","year":"2022","unstructured":"Peng M, Fan S, Li J, Zhou X, Liao Q, Tang F, Liu W. Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K\/AKT and Raf\/MEK\/ERK pathways in tongue squamous cell carcinoma. Genes Nutr. 2022;17:3. https:\/\/doi.org\/10.1186\/s12263-022-00705-y.","journal-title":"Genes Nutr"},{"key":"2794_CR41","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00280-022-04401-x","volume":"89","author":"W Wan","year":"2022","unstructured":"Wan W, Xiao W, Pan W, Chen L, Liu Z, Xu J. Isoprenylcysteine carboxyl methyltransferase is critical for glioblastoma growth and survival by activating Ras\/Raf\/Mek\/Erk. Cancer Chemother Pharmacol. 2022;89:401\u201311. https:\/\/doi.org\/10.1007\/s00280-022-04401-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2794_CR42","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.1128\/mcb.13.11.6615-6620.1993","volume":"13","author":"SG Macdonald","year":"1993","unstructured":"Macdonald SG, Crews CM, Wu L, Driller J, Clark R, Erikson RL, McCormick F. Reconstitution of the Raf-1-MEK-ERK signal transduction pathway in vitro. Mol Cell Biol. 1993;13:6615\u201320. https:\/\/doi.org\/10.1128\/mcb.13.11.6615-6620.1993.","journal-title":"Mol Cell Biol"},{"key":"2794_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.cd-20-0142","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D. BI-3406, a POTENT and selective SOS1-KRAS interaction inhibitor Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discov. 2021;11:142\u201357. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-0142.","journal-title":"Cancer Discov"},{"key":"2794_CR44","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2018-2162","author":"L Ru","year":"2018","unstructured":"Ru L, Yujie H, Hengrui L, James PD, Lin J. Abstract 2162: Comparing volatile and intravenous anesthetics in a mouse model of breast cancer metastasis. Can Res. 2018. https:\/\/doi.org\/10.1158\/1538-7445.am2018-2162.","journal-title":"Can Res"},{"key":"2794_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166941","author":"K Zi-Ran","year":"2024","unstructured":"Zi-Ran K, Shanshan J, Ji-Xuan H, Yaqi G, Yile X, Jinxian C, Qiang L, Jun Y, Xin Z, Jie H, Haoyan C, Yingxuan C, Huimin C, Jing-Yuan F. Deficiency of BCAT2-mediated branched-chain amino acid catabolism promotes colorectal cancer development. Biochimica et Biophysica Acta (BBA) \u2014 Molecular Basis of Disease. 2024. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166941.","journal-title":"Biochimica et Biophysica Acta (BBA) \u2014 Molecular Basis of Disease"},{"key":"2794_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167250","author":"L So Jeong","year":"2024","unstructured":"So Jeong L, SeongHo J, Sinyoung C, Chang Min K, Jung Ki Y, Seung-Hun O, Jong Hyup K, Young Y, JinKyeoung K. hsa-miR-CHA2, a novel microRNA, exhibits anticancer effects by suppressing cyclin E1 in human non-small cell lung cancer cells. Biochimica et Biophysica Acta (BBA) \u2014 Molecular Basis of Disease. 2024. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167250.","journal-title":"Biochimica et Biophysica Acta (BBA) \u2014 Molecular Basis of Disease"}],"updated-by":[{"DOI":"10.1007\/s12032-025-03136-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000}}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02794-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02794-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02794-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:39:14Z","timestamp":1768891154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02794-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2794"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02794-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The original version of this article unfortunately contained a mistake in figure 3. The figure 3 is corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12032-025-03136-y","URL":"https:\/\/doi.org\/10.1007\/s12032-025-03136-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"242"}}